[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know",
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $795.67, indicating a -0.08% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=c4bd767bd7c7dec61d4fbe5f1e5fe2af6ec255e1ffd8957c6b19f171d8d1deff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735080320,
      "headline": "Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know",
      "id": 132141629,
      "image": "https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $795.67, indicating a -0.08% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=c4bd767bd7c7dec61d4fbe5f1e5fe2af6ec255e1ffd8957c6b19f171d8d1deff"
    }
  },
  {
    "ts": null,
    "headline": "What's next for GLP-1 weight-loss drugs in 2025?",
    "summary": "GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly (LLY) exploring broader applications beyond weight management, including heart disease and sleep apnea treatments. Yahoo Finance Health Reporter Anjalee Khemlani dives into the details, analyzing the outlook for GLP-1 drugs as markets head into 2025. Also, catch Anjalee Khemlani highlight the three biggest catalysts for the healthcare industry expected in the new year. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith",
    "url": "https://finnhub.io/api/news?id=1f029c1f3a96f8489dbc131709c904839c81db9b41de6f89c972de54abae3e79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735069500,
      "headline": "What's next for GLP-1 weight-loss drugs in 2025?",
      "id": 132136182,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly (LLY) exploring broader applications beyond weight management, including heart disease and sleep apnea treatments. Yahoo Finance Health Reporter Anjalee Khemlani dives into the details, analyzing the outlook for GLP-1 drugs as markets head into 2025. Also, catch Anjalee Khemlani highlight the three biggest catalysts for the healthcare industry expected in the new year. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith",
      "url": "https://finnhub.io/api/news?id=1f029c1f3a96f8489dbc131709c904839c81db9b41de6f89c972de54abae3e79"
    }
  },
  {
    "ts": null,
    "headline": "3 biggest catalysts expected for healthcare in 2025",
    "summary": "After an eventful year in the pharmaceutical and biotech industries, what lies ahead for the health landscape in 2025? Yahoo Finance senior health reporter Anjalee Khemlani outlines the three biggest catalysts for change and innovation for healthcare in the new year, including GLP-1 weight-loss drugs and proposed regulations on pharmacy benefit managers (PBMs) from the second Trump administration. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Luke Carberry Mogan.",
    "url": "https://finnhub.io/api/news?id=d257b317d5d05997105840bc14ccb6a93eae24c968c53d9f1a66458a6df399af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735060800,
      "headline": "3 biggest catalysts expected for healthcare in 2025",
      "id": 132133934,
      "image": "https://s.yimg.com/ny/api/res/1.2/beEG94ULzRzpQ6PW9JqZAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/664ed980-c215-11ef-af3f-16c0199a30a2",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "After an eventful year in the pharmaceutical and biotech industries, what lies ahead for the health landscape in 2025? Yahoo Finance senior health reporter Anjalee Khemlani outlines the three biggest catalysts for change and innovation for healthcare in the new year, including GLP-1 weight-loss drugs and proposed regulations on pharmacy benefit managers (PBMs) from the second Trump administration. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Luke Carberry Mogan.",
      "url": "https://finnhub.io/api/news?id=d257b317d5d05997105840bc14ccb6a93eae24c968c53d9f1a66458a6df399af"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=6eb528bd927c1a7302bc1a734dfeee87d3041524b8b16ded8d0c69b028e22979",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735057980,
      "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
      "id": 132145559,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=6eb528bd927c1a7302bc1a734dfeee87d3041524b8b16ded8d0c69b028e22979"
    }
  },
  {
    "ts": null,
    "headline": "Retail investors buy Novo dip after disappointing weight-loss drug data",
    "summary": "U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected obesity drug data offered a rare dip-buying opportunity, according to Vanda Research.  Daily net flows climbed to $15.6 million from $0.49 million a day earlier, after eagerly anticipated data showed Novo's experimental drug, CagriSema, helped patients cut 22.7% of their weight—short of the anticipated 25%.  Novo competes with U.S. rival Eli Lilly in the burgeoning market for weight-loss treatments, which is projected to exceed $150 billion in revenue within the next decade.",
    "url": "https://finnhub.io/api/news?id=51043bbf8ece511da1188efaa73a21755ab63c32c79cae5bf2dd392df87306db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735051107,
      "headline": "Retail investors buy Novo dip after disappointing weight-loss drug data",
      "id": 132133260,
      "image": "https://media.zenfs.com/en/reuters.com/f1c529dd8a330a8c05b29f0c5bff440f",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected obesity drug data offered a rare dip-buying opportunity, according to Vanda Research.  Daily net flows climbed to $15.6 million from $0.49 million a day earlier, after eagerly anticipated data showed Novo's experimental drug, CagriSema, helped patients cut 22.7% of their weight—short of the anticipated 25%.  Novo competes with U.S. rival Eli Lilly in the burgeoning market for weight-loss treatments, which is projected to exceed $150 billion in revenue within the next decade.",
      "url": "https://finnhub.io/api/news?id=51043bbf8ece511da1188efaa73a21755ab63c32c79cae5bf2dd392df87306db"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?",
    "summary": "NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term growth potential.",
    "url": "https://finnhub.io/api/news?id=15af1c6843745ea6e0fe975edc446fe265064dcb380bbaf9225668c0a5cab277",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735047960,
      "headline": "Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?",
      "id": 132133261,
      "image": "https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term growth potential.",
      "url": "https://finnhub.io/api/news?id=15af1c6843745ea6e0fe975edc446fe265064dcb380bbaf9225668c0a5cab277"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Dec 24, 2024",
    "summary": "Companies In The Article Are: WMT, QCOM, LLY, HMC",
    "url": "https://finnhub.io/api/news?id=61eee778340eeecf91c540781768d7d9957e386778ba5c8b98c2b269f1c66473",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735043640,
      "headline": "Company News for Dec 24, 2024",
      "id": 132131685,
      "image": "https://media.zenfs.com/en/zacks.com/cbb8d8633afa6c2ccd4d034828cb4789",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies In The Article Are: WMT, QCOM, LLY, HMC",
      "url": "https://finnhub.io/api/news?id=61eee778340eeecf91c540781768d7d9957e386778ba5c8b98c2b269f1c66473"
    }
  },
  {
    "ts": null,
    "headline": "With EPS Growth And More, Eli Lilly (NYSE:LLY) Makes An Interesting Case",
    "summary": "Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...",
    "url": "https://finnhub.io/api/news?id=7308664d886031e6430a0724296771d5504d2f85f1f074a6b369c592816fcddf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735041621,
      "headline": "With EPS Growth And More, Eli Lilly (NYSE:LLY) Makes An Interesting Case",
      "id": 132131686,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/1b6847ee48493a5698212be177362a15",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...",
      "url": "https://finnhub.io/api/news?id=7308664d886031e6430a0724296771d5504d2f85f1f074a6b369c592816fcddf"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived",
    "summary": "Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock and this lucrative market.",
    "url": "https://finnhub.io/api/news?id=2970f7e0074a68e09970989c578c866ff3eefc8007a8c08dcbed1b49265be650",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735039800,
      "headline": "Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived",
      "id": 132133129,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305291/image_2158305291.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock and this lucrative market.",
      "url": "https://finnhub.io/api/news?id=2970f7e0074a68e09970989c578c866ff3eefc8007a8c08dcbed1b49265be650"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Time And Patience Ran Out (Rating Downgrade)",
    "summary": "Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained turnaround is close for PFE stock.",
    "url": "https://finnhub.io/api/news?id=5bb5d990ccf7462017b856c1ce4722c823d4235433be26b2bab9f8c820190d1d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735029000,
      "headline": "Pfizer: Time And Patience Ran Out (Rating Downgrade)",
      "id": 132131133,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491484031/image_1491484031.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained turnaround is close for PFE stock.",
      "url": "https://finnhub.io/api/news?id=5bb5d990ccf7462017b856c1ce4722c823d4235433be26b2bab9f8c820190d1d"
    }
  },
  {
    "ts": null,
    "headline": "8 Giant Stock Champs In 2024 Predicted To Win Again In 2025",
    "summary": "8 Giant Stock Champs In 2024 Predicted To Win Again In 2025",
    "url": "https://finnhub.io/api/news?id=dd5a5fe871a65e06a4958c7117348e6b5914ebd842b5173f72a0f3a7e629bd37",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735027241,
      "headline": "8 Giant Stock Champs In 2024 Predicted To Win Again In 2025",
      "id": 132145149,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "8 Giant Stock Champs In 2024 Predicted To Win Again In 2025",
      "url": "https://finnhub.io/api/news?id=dd5a5fe871a65e06a4958c7117348e6b5914ebd842b5173f72a0f3a7e629bd37"
    }
  }
]